Cargando…

Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy

BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Stokes, Michael B., Thoi, Fiona, Scherer, Daniel J., Win, Kyi T. H., Kaye, David M., Teo, Karen S., Sanders, Prashanthan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713956/
https://www.ncbi.nlm.nih.gov/pubmed/36451214
http://dx.doi.org/10.1186/s12968-022-00898-6
_version_ 1784842120623816704
author Stokes, Michael B.
Thoi, Fiona
Scherer, Daniel J.
Win, Kyi T. H.
Kaye, David M.
Teo, Karen S.
Sanders, Prashanthan
author_facet Stokes, Michael B.
Thoi, Fiona
Scherer, Daniel J.
Win, Kyi T. H.
Kaye, David M.
Teo, Karen S.
Sanders, Prashanthan
author_sort Stokes, Michael B.
collection PubMed
description BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP. METHODS: A retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner. RESULTS: The mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV). CONCLUSION: MA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings.
format Online
Article
Text
id pubmed-9713956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97139562022-12-02 Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy Stokes, Michael B. Thoi, Fiona Scherer, Daniel J. Win, Kyi T. H. Kaye, David M. Teo, Karen S. Sanders, Prashanthan J Cardiovasc Magn Reson Research BACKGROUND: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP. METHODS: A retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner. RESULTS: The mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV). CONCLUSION: MA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings. BioMed Central 2022-12-01 /pmc/articles/PMC9713956/ /pubmed/36451214 http://dx.doi.org/10.1186/s12968-022-00898-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Stokes, Michael B.
Thoi, Fiona
Scherer, Daniel J.
Win, Kyi T. H.
Kaye, David M.
Teo, Karen S.
Sanders, Prashanthan
Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title_full Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title_fullStr Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title_full_unstemmed Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title_short Cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
title_sort cardiovascular magnetic resonance imaging characteristics in patients with methamphetamine-associated cardiomyopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713956/
https://www.ncbi.nlm.nih.gov/pubmed/36451214
http://dx.doi.org/10.1186/s12968-022-00898-6
work_keys_str_mv AT stokesmichaelb cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT thoifiona cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT schererdanielj cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT winkyith cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT kayedavidm cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT teokarens cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy
AT sandersprashanthan cardiovascularmagneticresonanceimagingcharacteristicsinpatientswithmethamphetamineassociatedcardiomyopathy